###### Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ☑ Strong synergy has been observed between the numerous inhibitors targeting hepatitis C virus (HCV) entry and antiviral agents targeting other stages of the HCV lifecycle. The origin of the synergy remains poorly understood. • WHAT QUESTION DID THIS STUDY ADDRESS? ☑ We constructed a mathematical model of HCV viral kinetics *in vitro* to unravel the mechanism of synergy between the drugs. • WHAT THIS STUDY ADDS TO OUR KNOWLEDGE ☑ Our model demonstrates that heterogeneity of entry receptor expression levels across cells, leading to complementary activity of drugs across different cell subpopulations, can give rise to the observed synergy between the HCV entry inhibitors and drugs of other classes. Synergy may thus arise not only from molecular/intracellular level interactions between drugs but also from heterogeneities at the cell population level. • HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS ☑ The mechanism of synergy that we have identified may enable more accurate interpretation of drug efficacies in combination and facilitate rational optimization of treatment with HCV entry inhibitors.

Hepatitis C virus (HCV) entry into target cells involves the viral envelope proteins E1 and E2 and several cell surface receptors including scavenger receptor class B type 1 (SR-B1),[@b1] CD81,[@b2] tight-junction proteins claudin-1 (CLDN1)[@b3] and occludin (OCLN),[@b4] Niemann-Pick C1-Like 1 (NPC1L1),[@b5] and transferrin receptor 1 (Tfr1).[@b6] Additionally, host factors such as epidermal growth factor receptor (EGFR)[@b7], ephrin receptor A2 (EphA2),[@b7] and HRas[@b8] have been shown to modulate HCV entry. Entry inhibitors (EIs) targeting viral envelop proteins or host receptors have been able to prevent infection *in vitro* and in a mouse model[@b5]--[@b15] and present a promising new class of anti-HCV drugs. Indeed, two EIs, ITX 5061, which targets SR-B1, and erlotinib, which targets EGFR, are in clinical trials and several compounds targeting other aspects of the HCV entry process are in development.[@b16],[@b17]

Recent studies have observed strong synergy between EIs and other classes of direct-acting antiviral agents (DAAs) or host-targeting agents (HTAs) that are in use or in clinical development.[@b9],[@b18] The EIs investigated in these studies are monoclonal antibodies targeting CD81, CLDN1, or SR-B1, and small molecule inhibitors targeting SR-B1 (ITX 5061), EGFR (erlotinib), or EphA2 (dasatinib). The DAAs investigated are protease inhibitors (telaprevir, boceprevir, simeprevir, and danoprevir), an NS5A inhibitor (daclatasvir), and polymerase inhibitors (sofosbuvir and mericitabine). The HTAs investigated are a cyclophilin inhibitor (alisporivir) and pegylated interferon α.

Synergy implies that in combination lower drug dosages can yield the desired efficacy. Consequently, unraveling the mechanism(s) underlying this observed synergy assumes importance: it would facilitate the rational identification of optimal drug dosages that would maximize treatment response, yielding guidelines for the use of EIs in combination with other drugs. One possibility that may give rise to synergy between an EI and another drug is the existence of an interaction, as yet unknown, between the HCV entry process and the step of the HCV lifecycle targeted by the other drug. For instance, if blocking one of the entry receptors were also to affect viral replication via signaling downstream of the entry receptor, then synergy between EIs and viral polymerase inhibitors may arise. Such a possibility, however, appears unlikely because EIs display synergy with drugs from several classes and interactions between each of the steps of the HCV lifecycle targeted by the latter drugs and the viral entry process are not foreseen. Another possibility is that EIs act on strains that carry resistance mutations to the other drug, thus increasing the overall genetic barrier of the combination. EIs, however, also exhibit synergy with interferon, which acts by stimulating the host-immune response, and against which resistant strains are not expected to arise. Thus, while the above mechanisms might contribute to synergy in specific cases, a more general mechanism appears to underlie the broadly observed synergy between EIs and other drugs.

Here we explore an alternative hypothesis that could explain the broad synergy between EIs and other drugs. We argue that synergy between an EI and another drug could arise from the complementary activities of the two drugs across cell subpopulations expressing different levels of entry receptors (**Figure** [1](#fig01){ref-type="fig"}). By entry receptors we mean the cell or viral surface proteins or other host factors listed above that affect HCV entry. A distribution of the expression level of entry receptors is typically observed across cells in culture.[@b19] Entry efficiency increases with receptor expression.[@b19],[@b20] Blocking virus entry into cells with higher receptor expression levels therefore requires larger dosages of the EI. Infection of such cells, however, can be blocked more readily by the other drug, which is unaffected by the efficiency of the entry process. Thus, when used in combination, the EI need only target cells with low entry receptor expression levels, which is accomplished at lower dosages, leading to the observed synergy.

![Schematic of the hypothesis. The expression level of an entry receptor varies across cells (left). The entry inhibitor is more effective in blocking the infection of cells with low receptor expression, whereas a DAA or an HTA of another class is more effective in blocking the infection of cells with high receptor expression (right). This complementary activity of the drugs across subpopulations of cells may give rise to synergy.](psp40004-0445-f1){#fig01}

To test this hypothesis, we constructed two mathematical models: a conceptual model that serves to elucidate the key underpinnings of the hypothesis, and a more comprehensive model that mimics experiments. We found, interestingly, that although, as expected, the drugs acted independently at the single-cell level, they displayed synergy at the cell-population level and that the extent of synergy increased with increase in the heterogeneity of entry receptor expression levels across cells.

METHODS
=======

Conceptual model
----------------

### Framework

We first constructed a simple, conceptual model where target cells,, consisted of only two subpopulations, and, with cells expressing more of a particular entry receptor than (**Figure** [2](#fig02){ref-type="fig"}**a**). Otherwise, the cells were assumed to be identical. We let the cells be exposed to HCV virions, *V*, in the presence or absence of drugs. We assumed that the EI targeted the receptor that distinguished from. Accordingly, the inhibitor blocked the infection of more efficiently than that of. The other drug (a DAA or an HTA of another class) worked independently of the entry receptor and thus blocked the infection of and to the same extent. We constructed the following equations to describe the ensuing viral kinetics.

![Schematic of the models. (a) Conceptual model of viral kinetics following exposure of target cells expressing two discrete levels of the entry receptor (low or high) to HCV virions (left). An entry inhibitor blocks the infection of receptor-low cells more effectively, whereas a DAA or an HTA of another class blocks the infection of cells independently of receptor expression (right). (b) Model of viral kinetics *in vitro* (right) following exposure of target cells with a distribution of the entry receptor expression level (left) to HCV virions. The dependence of susceptibility to infection on entry receptor expression,, increases and the efficacy of entry inhibitors,, decreases with increase in the receptor expression level. The other symbols employed are defined in the Methods.](psp40004-0445-f2){#fig02}

Here, target cells proliferate and die with rate constants and, respectively. is the carrying capacity of the cell culture and is the second-order infection rate constant. Infection of target cells produces the respective infected cells. Based on recent observations of HCV-induced cell cycle arrest *in vitro*, we neglected the proliferation of infected cells.[@b21],[@b22] Infected cells die with an enhanced death rate constant due to HCV-induced cytopathicity *in vitro*.[@b23] Free virions are produced from each infected cell and are cleared, with rate constants and, respectively. When drugs are present, we assumed that infection is inhibited by blocking the infection of and with net efficacies and, respectively. (We recognize that the other drug may lower viral production instead, but because viral production and clearance are rapid, the resulting pseudo-steady state,[@b20],[@b24], effectively translates to a lowering of infection; see **Supplementary Text**.)

### Drug efficacies

We obtained and as follows. In the presence of the EI alone, we defined and. We assumed the dose--response relationship of drugs to follow a Hill function. Accordingly, the EI at concentration blocked the infection of and with the defined efficacies and, respectively, where and are the drug concentrations of the EI required to block the infection of and by 50% and and are the Hill coefficients.

In the presence of the other drug alone, we let. The other drug at concentration blocked the infection of both and with efficacy. Again, is the concentration of the other drug required to block the infection of both and by 50% and is the Hill coefficient.

In the presence of both drugs, we assumed that the drugs acted independently within each subpopulation. Accordingly, we obtained and by setting the combination index ()[@b25] (defined below) to unity in both populations. We considered first the subpopulation. The efficacy when the EI at concentration and the other drug at concentration are used together is given by enforcing independence based on: where and are concentrations of the EI and the other drug required to block the infection with the same efficacy when they are used alone. Using and in the dose--response relationships of the drugs above, it follows that and. Substituting the latter expressions in Eq. [4](#m4){ref-type="disp-formula"} yielded solving which yielded for the concentrations and employed. Similarly, solving the corresponding equation, yielded, the combined efficacy in the subpopulation *T*~2~.

Using and thus obtained, Eqs. [1](#m1){ref-type="disp-formula"} [2](#m2){ref-type="disp-formula"} [3](#m3){ref-type="disp-formula"} can be solved to predict viral kinetics under exposure to any drug levels and given the initial distribution of the cell population into the two subpopulations. We assumed that at the start of the infection a fraction of the target cells is of type. We varied between 0 and 1. Further, we assumed that infection was seeded by free virions and no infected cells existed at the start.

### Synergy

The predictions of viral kinetics were employed to assess the synergy between the drugs. This involved solving the inverse problem of identifying drug concentrations for a desired level,, of inhibition of infection at a fixed timepoint during the course of infection, with the inhibition measured in terms of the fraction of cells infected. We first fixed to, say, 50%. We solved the model equations above first without drugs and predicted the number of infected cells at the desired timepoint, say, 3 days postinfection. We next solved the equations in the presence of the EI alone and identified that concentration at which the number of infected cells was lowered by the factor *x* at the desired timepoint. We repeated the procedure with the other drug alone and identified the corresponding concentration. We finally solved the equations with the drugs used simultaneously and identified the concentrations and at which the same level of inhibition was achieved. To minimize our search space, following experiments,[@b9],[@b18] we let the ratio of and be equal to the ratio of and; i.e.,. The combination index, then yielded the extent of synergy (or antagonism) between the drugs at the level of inhibition considered. (Use of the alternative expression,, did not alter our findings; see **Supplementary** **Figure 1**.) We repeated the procedure for different values of (=50%, 75% and 90%) as in the experiments.[@b9],[@b18]

Model of HCV viral kinetics *in vitro*
--------------------------------------

### Framework

We next considered *in vitro* experiments where a population of target cells is exposed to a population of HCV virions with or without drugs (**Figure** [2](#fig02){ref-type="fig"}**b**). The cell population was assumed to exhibit a distribution of the expression level of the entry receptor above. We therefore divided the target cells into subpopulations, denoted by, where, with cells expressing the entry receptor in a narrow range around molecules per unit area. The following equations describe the ensuing viral kinetics:

Here,,,,,, and are the same as in Eqs. [1](#m1){ref-type="disp-formula"} [2](#m2){ref-type="disp-formula"} [3](#m3){ref-type="disp-formula"}. We additionally recognized that the efficiency of entry increases with the expression level of the entry receptor, *n~i~*. We modeled this efficiency using the relative susceptibility of cells *T~i~* to virus entry. Based on previous studies,[@b20],[@b26] we let *S~i~* depend on entry receptor expression following a Hill function,, where is the Hill coefficient and is the entry receptor expression level at which. Note that when, and when,. is thus the infection rate of cells expressing the entry receptor in excess.

### Drug efficacies

Here we adopted a more mechanistic approach to evaluate the efficacy of the EI, based on the assumption that it targeted the entry receptor that distinguished the different cell subpopulations. (Note that the empirical approach based on the Hill function employed in the conceptual model above can also be used here.) In the presence of the inhibitor, thus, the number of free receptors,, available for HCV entry decreased due to the formation of the receptor--inhibitor complexes,. The susceptibility of cells to infection in the presence of the EI consequently reduced to. Assuming complex formation to be rapid, we estimated the number of complexes formed using reaction equilibrium to be, where is the equilibrium dissociation constant of the complexes. Mass balance on the receptor expression level,, then yielded and. Substituting the latter expression for in the expression above yielded. We recognized next that, where is the efficacy of the EI in cells *T~i~*, when used alone. Using the expression for, combining it with the expression for and rearranging terms yielded as a function of the receptor expression level,:

By letting, we obtained from the above expression the concentration of the EI required to block the infection of by 50%:.

Like in the conceptual model, the other drug was assumed to block the infection of cells in each subpopulation with efficacy, independently of the expression level of the entry receptor. (Relaxing this assumption by allowing the latter efficacy also to exhibit an independent distribution across cells led to greater synergy; see **Supplementary Text, Supplementary** **Figure 2**.)

In the presence of the EI alone,. In the presence of the other drug alone,. In the presence of both the drugs at concentrations and, respectively, the combined efficacy,, can be obtained by solving the equation below, derived following the same procedure employed for Eq. [5](#m5){ref-type="disp-formula"}, i.e., by enforcing:

Knowledge of the efficacies,, allowed us to solve Eqs. [8](#m8){ref-type="disp-formula"} [9](#m9){ref-type="disp-formula"} [10](#m10){ref-type="disp-formula"} and predict the resulting viral kinetics for any and given an initial distribution of cells in the various subpopulations.

### Synergy

To estimate synergy, we followed the same procedure employed in the conceptual model above, where we first identified the concentrations and of the EI and the other drug required for achieving a desired level of inhibition, *x*, when used alone. We then determined the concentrations and at which the same level of inhibition was achieved when the drugs were used together., evaluated using Eq. [7](#m7){ref-type="disp-formula"}, then provided a measure of synergy.

Data
----

We considered data from previous cell culture studies where human hepatoma-derived cells were exposed to cell culture-derived HCVcc virions in the presence of EIs and/or DAAs and HTAs of other classes. In these experiments, target cells proliferate, die, and get infected by HCVcc virions. Free virions are in turn produced by infected cells and are lost due to natural degradation. Viral infection was assessed using luciferase activity and was calculated at 50, 75, and 90% inhibition to assess synergy.[@b9],[@b18]

Calculations and model parameters
---------------------------------

We solved the model equations using computer programs written in MatLab (MathWorks, Natick, MA) and/or Berkeley Madonna ([www.berkeleymadonna.com](http://www.berkeleymadonna.com)) and computed the time-evolution of all of the subpopulations of uninfected cells,, infected cells,, and the viral titer,. The extent of inhibition was obtained as the ratio of the total population of infected cells,, in the presence of drug(s) to that in the absence of drugs at day 3 postinfection. Using viral load instead of infected cells to quantify the extent of inhibition did not alter our findings (**Supplementary** **Figure 3**). We employed model parameters that described the kinetics of infection of Huh-7.5 cells with JFH1 virus[@b20] (**Figure** [3](#fig03){ref-type="fig"}). We also examined the sensitivity of our model predictions to variations in these parameter values (**Supplementary** **Figure 4**).

![Predictions of the conceptual model. (a) The efficacy of the entry inhibitor, and, in blocking the infection of cells and, respectively, for different entry inhibitor concentrations,, and (b) the corresponding median-effect plot. represents the fraction of infection events prevented by the drug. The corresponding median effect equation,, yields as the logarithm of the ratio of the number of infection events inhibited by the drug to the number uninhibited. (c) The efficacy of a DAA or an HTA in blocking the infection of cells and,, for different drug concentrations,, and the corresponding median-effect plot. The efficacy of the combination in blocking the infections of and, and, (d) for fixed () and different and (e) for fixed () and different. (f) Combination index, *CI*, determined at 90% inhibition of the cumulative level of infection at day 3 postinfection for different values of, the fraction of cells expressing high receptor expression levels,, and, the ratio of and. Drug concentrations are normalized by the respective values. Parameter values^20^: *λ = *0.44 d^−1^; *μ* = 1.7 × 10^−4^ d^−1^; *δ* = 1.1 × 10^−2^ d^−1^; *β* = 1.2 × 10^−4^ ml·(ffu·d)^−1^; *p = *2.78 ffu·(ml·d)^−1^; and *c* = 23.2 d^−1^. We assumed, representative of *in vitro* cultures.[@b45] The Hill coefficients,, and. In (d) and (e),. Initial conditions: target cells,, with and; virions, (ffu stands for focus-forming units); and infected cells,.](psp40004-0445-f3){#fig03}

RESULTS
=======

Conceptual model
----------------

To elucidate the role of heterogeneity in receptor expression in the observed synergy between an EI and a drug of another class, we constructed a conceptual model where target cells in culture expressed one of two discrete levels (high or low) of one entry receptor and were identical otherwise (**Figure** [2](#fig02){ref-type="fig"}**a**; **Methods**). Within each cell, and hence subpopulation, we assumed that the drugs acted independently and examined whether they exhibited synergy at the cell population level by computing the combination index ()., and indicate synergy, additivity, and antagonism, respectively.

### Efficacy of individual drugs

In the two cell subpopulations, denoted and, the EI acted with different efficacies. The difference in the receptor expression level between the two subpopulations was assumed to affect the; specifically,, indicating greater efficacy of the inhibitor in the subpopulation (**Figure** [2](#fig02){ref-type="fig"}**a**). The efficacies in the two subpopulations, denoted and, respectively, increased with drug concentration in a sigmoidal manner (**Figure** [3](#fig03){ref-type="fig"}**a**) (yielding a linear median-effect curve (**Figure** [3](#fig03){ref-type="fig"}**b**). Further, as increased relative to, higher drug levels were required to achieve the desired.

The dose--response curve of the other drug (a DAA or HTA of another class) also followed a sigmoidal pattern, but was the same for the two cell subpopulations (**Figures** [2](#fig02){ref-type="fig"}**a**, [3](#fig03){ref-type="fig"}**c**).

### Efficacy of drugs in combination

We examined next the combined effect of the two drugs in each cell subpopulation. The independent activities of the drugs implied that in each subpopulation. Thus, for a range of concentrations of the EI,, and a fixed concentration of the other drug,, we computed the net efficacy of the combination in the subpopulation, using Eq. [5](#m5){ref-type="disp-formula"} above. When was small,, the efficacy corresponding to alone (**Figure** [3](#fig03){ref-type="fig"}**d**). As increased, rose in a sigmoidal manner and reached 1. For the subpopulation, we found that much higher values of were required to achieve the same efficacies as in (**Figure** [3](#fig03){ref-type="fig"}**d**). The activity of the EI was thus more prominent in the subpopulation. We repeated the calculations for fixed and a range of values of (**Figure** [3](#fig03){ref-type="fig"}**e**). In the subpopulation,, the efficacy corresponding to alone, when was small and increased to 1 for large values of. The trend was similar in the subpopulation. However, the influence of the other drug was evident at much lower values of in than in; began to rise above at nearly 10-fold lower than when began to rise above. The influence of the other drug was thus more prominent in the subpopulation.

### Synergy

To describe the scenario when both types of cells, and, were present in culture, we solved the viral kinetics equations (Eqs. [1](#m1){ref-type="disp-formula"}[2](#m2){ref-type="disp-formula"}[3](#m3){ref-type="disp-formula"}) using the efficacies illustrated above, and estimated the drug levels required to achieve 90% inhibition of infection at day 3 postinfection. The drug levels then yielded (via Eq. [7](#m7){ref-type="disp-formula"}). We performed calculations over a range of values of (), the fraction of cells of type at the start of infection, and different ratios of and, denoted by (**Figure** [3](#fig03){ref-type="fig"}**f** and **Supplementary** **Figure** **5**). When was either 0 or 1, a single cell type existed in the population and equaled unity, indicating independence between the drugs. For intermediate values of, where the cell population was heterogeneous, was smaller than 1, indicating synergy. Similarly, when was 1, indicating that the EI worked identically in the two subpopulations, heterogeneity was again lost and for all values. As decreased, indicating greater distinction between the two subpopulations, decreased, indicating greater synergy between the drugs. Our model thus predicted synergy between the drugs () as arising from the heterogeneity of the underlying cell population and the resulting complementary activity of the drugs across cells.

With this conceptual understanding, we examined next whether a model that mimicked *in vitro* studies with cells exhibiting a continuous distribution of receptor expression levels also displayed synergy due to the same underlying principle.

Model of HCV viral kinetics *in vitro*
--------------------------------------

We divided target cells into several subpopulations with distinct receptor expression levels (**Figure** [2](#fig02){ref-type="fig"}**b**) to mimic the distribution of receptor expression levels observed in cell culture studies. Further, we allowed entry efficiency to depend on receptor expression and estimated EI efficacy by quantifying its ability to block the entry receptor in question. The efficacy of the other drug remained independent of receptor expression. In each cell, the action of the two drugs was again assumed to be independent of each other. We estimated based on a desired level of inhibition at different times postinfection to assess synergy at the cell population level (**Methods**).

### Drug efficacies

The susceptibility of a cell to infection increased with receptor expression in a sigmoidal manner (**Figure** [4](#fig04){ref-type="fig"}**a**). The efficacy of the EI correspondingly decreased with increase in receptor expression (**Figure** [4](#fig04){ref-type="fig"}**b**). The efficacy of the other drug remained constant across subpopulations. We defined the combined efficacy of the drugs within each subpopulation,, to be independent (by letting). showed a dependence on receptor expression,, as follows (**Figure** [4](#fig04){ref-type="fig"}**b**). When was small, the EI was highly efficacious and more potent than the other drug. was then close to the efficacy of the EI. When was large, the EI was compromised, whereas the other drug continued to exert its antiviral activity. was then well approximated by the efficacy of the latter drug. At intermediate, gradually switched between the two extremes (**Figure** [4](#fig04){ref-type="fig"}**b**).

![Predictions of the model of HCV kinetics *in vitro*. (a) Dependence of the susceptibility of a cell to infection,, on its receptor expression level,. (b) Efficacy of the entry inhibitor,, and the other drug,, and the combined efficacy of the two drugs,, as functions of. (c) The log-normal distribution,, of the receptor expression level across cells, where is the mean and is the standard deviation of. (d) Combination index, *CI*, determined at 90% inhibition of the cumulative level of infection at day 3 postinfection for different values of. The concentrations of the entry inhibitor and the other drug are normalized by and, respectively. (Note that is directly proportional to; see Methods.) Parameters:,, and. In (b) and. Initial conditions: The fraction,, of target cells belonging to the subpopulation follow the log-normal distribution above. The other parameters and initial conditions are the same as those listed in Figure 3.](psp40004-0445-f4){#fig04}

### Heterogeneity in receptor expression and synergy

With the above estimates of, we solved model equations (Eqs. [8](#m8){ref-type="disp-formula"} [9](#m9){ref-type="disp-formula"} [10](#m10){ref-type="disp-formula"}) to predict the effect of drugs on HCV viral kinetics *in vitro* (**Supplementary** **Figure 6**) and estimated. (Note that the model equations are consistent with *in vitro* data of viral kinetics.[@b20],[@b26]) We considered different levels of heterogeneity in the receptor expression level: as, the standard deviation of the log-normal distribution of receptor expression levels, increased, heterogeneity in receptor expression across cells increased (**Figure** [4](#fig04){ref-type="fig"}**c**).

We found that remained equal to 1 when the receptor expression across cells was homogeneous () (**Figure** [4](#fig04){ref-type="fig"}**d**). This followed from the independence of the activities of the drugs in individual cells. We found, interestingly, that when the receptor expression across cells became heterogeneous (), became less than 1, suggesting synergy. decreased as the heterogeneity in receptor expression () increased (**Figure** [4](#fig04){ref-type="fig"}**d**) as the complementary activity of the drugs at the population level became more prominent, consistent with our conceptual model (**Figure** [3](#fig03){ref-type="fig"}**f**). was largely insensitive to model parameters (**Supplementary** **Figure 4**) or the time postinfection when the assessment of synergy is made (**Supplementary** **Figure 7**). Our prediction of synergy due to heterogeneity in receptor expression is thus robust to changes in model parameter values.

DISCUSSION
==========

Recent studies have shown strong synergy between EIs and DAAs or HTAs of other classes.[@b9],[@b18] Unraveling the mechanism of this observed synergy may facilitate optimization of combination treatments involving EIs. Mathematical models of HCV viral kinetics have been employed successfully to determine the effectiveness of treatment,[@b24],[@b27]--[@b29] identify mechanisms of the action of drugs,[@b30],[@b31] and to analyze patient data[@b24],[@b27] and cell culture experiments.[@b20],[@b26],[@b32],[@b33] In this study, advancing a previously developed mathematical model of HCV viral kinetics *in vitro*[@b20],[@b26] to account explicitly for drug action, we suggest that heterogeneity of receptor expression across cells and the resulting complementary action of drugs across distinct cell subpopulations may underlie the synergy between EIs and other drugs.

Synergy between drugs is thought to arise from an underlying interaction between the drugs or between the processes, pathways, and/or molecules they target.[@b34] For instance, we demonstrated recently that DAAs targeting viral replication can alter the systems-level properties of the interferon signaling network and improve responsiveness of cells to type I interferon.[@b28] Our current study presents an alternative explanation of the observed synergy between EIs and drugs of other classes based not on interactions between the drugs but on their complementary activities at the cell population level. Whereas EIs are likely to be more effective in blocking infection of cells with low entry receptor expression levels, the other drugs, whose effectiveness is independent of the entry receptor expression level, are expected to block the infection of cells with high entry receptor expression levels, bringing about synergy. Experiments that measure the effectiveness of drugs as a function of entry receptor expression levels would provide tests of our proposed explanation.

HCV entry into target cells can occur by cell-free virions or cell-to-cell transmission.[@b16],[@b17] Although in our model we explicitly considered entry by cell-free virions, the model is applicable to entry via both modes.[@b20] The viral titer is typically proportional to the population of infected cells, so that the infection rate constant in our model can be thought of as an effective rate constant for infection by both modes. We recognize, however, that if the EI considered blocks entry by one mode alone, then entry by the other mode can predominate, compromising drug efficacy and the resulting synergy.[@b35]

The mode of synergy elucidated by our study may have broader applicability. We anticipate this mode of synergy to arise whenever two drugs target different molecules that exhibit distributions of their expression levels across cells and/or viral particles, allowing complementary activity of the drugs at the cell population level. Variations in the expression levels of molecules are intrinsic to cells.[@b36],[@b37] Viral envelope proteins and other enzymes are also expected to exhibit intrinsic variations in expression levels.[@b38] This heterogeneity could thus explain at least in part the observed synergy between small molecule inhibitors of different HCV targets in recent *in vitro* studies,[@b39]--[@b41] between EIs targeting different aspects of the HCV entry process,[@b10],[@b18],[@b42],[@b43] and perhaps also between several anti-HIV drugs.[@b44] Accounting for this new mode of synergy may be important for accurate quantification of drug action and rational treatment optimization.
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